Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional Responses in Livers of Adult and Newborn Mice to Aflatoxin B1

ABSTRACT: Susceptibility to the hepatocarcinogen Aflatoxin B1 (AFB1) varies among species and with age. Mice are refractory to carcinogenic and toxic effects of AFB1; however, B6C3F1 mice show transient sensitivity if dosed shortly after birth. We compared age-related differences in gene expression and transcriptional responses to AFB1 in livers of newborn (4-day-old) and adult mice. Keywords: Transcriptional response to a carcinogen

ORGANISM(S): Mus musculus

PROVIDER: GSE4740 | GEO | 2009/01/01

SECONDARY ACCESSION(S): PRJNA95681

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of mouse livers of adult and newborn animal response to Aflatoxin B1

Project description:Susceptibility to the hepatocarcinogen Aflatoxin B1 (AFB1) varies among species and with age. Mice are refractory to carcinogenic and toxic effects of AFB1; however, B6C3F1 mice show transient sensitivity if dosed shortly after birth. We compared age-related differences in gene expression and transcriptional responses to AFB1 in livers of newborn (4-day-old) and adult mice. Experiment Overall Design: Experiments were carried out under the protocol approved by MIT Animal Care Committee. Pregnant C57BL/6J female mice, mated to C3H/HeJ males, and adult (at least 60 day-old) B6C3F1/J hybrid F1 male mice (C57BL/6J female x C3H/HeJ male) were obtained from Jackson Labs. They were housed in plastic cages (one per cage) under controlled environmental conditions and 12 h light/dark cycle. Food and water were supplied ad libitum. After female mice gave birth, the male B6C3F1 pups were dosed at 4 days by a single i.p. injection of AFB1 (6 mg/kg body weight) in DMSO (10 ml/kg body weight) or the same volume of just DMSO. The treatments were always performed at the same time of the day and the pups were returned to their mothers until they were sacrificed 4 or 24 h after treatment. Adult B6C3F1 males were treated with the same doses and volumes of AFB1 or DMSO after an acclimation period of at least two weeks and sacrificed 4 or 24 hours after treatment. We noticed that injection of a volume of 10 ml/kg (whether AFB1 or vehicle alone) is tolerated poorly by adult animals and thus another group of adult animals was added which was treated with the same (6 mg/kg) dose of AFB in lower (5 ml/kg) volume. Corresponding vehicle control animals (5ml/kg DMSO) were also used. In addition, untreated controls were used and sacrificed together with the treated animals. Three independant bilogical replicates were used for each experimental point. Total RNA was isolated from livers and processed according to standard Affymetrix protocol.

2009-01-14 | E-GEOD-4740 | biostudies-arrayexpress

Early target genes of aflatoxin B1 in human hepatic cells

Project description:Comparison of gene expression profiles induced by the mycotoxin, aflatoxin B1 (AFB1), in primary human hepatocytes and HepaRG cells. Initial mechanisms involved in the complex multistep process leading to malignant transformation by chemicals remain largely unknown. We have analysed changes in gene expression profiles in primary human hepatocytes and differentiated human hepatoma HepaRG cells after a 24 h treatment with 0.05 or 0.25µM aflatoxin B1 (AFB1), a potent genotoxic hepatocarcinogen.

2010-12-07 | GSE25844 | GEO

Early target genes of aflatoxin B1 in human hepatic cells

2010-12-07 | E-GEOD-25844 | biostudies-arrayexpress

Transcription profiling of mouse liver and cecum after exposure to aflatoxin B1 (AFB1) and/or Helicobacter hepaticus

Project description:We evaluated aflatoxin B1-induced liver tumor promotion by H. hepaticus. Microarrays of liver and cecum from female mice were used to evaluate the individual and combined transcriptional effects of AFB1 and H. hepaticus Experiment Overall Design: C3H/HeN mice were inoculated with 7 ug/g BW AFB1 or vehicle IP at 10 days of age, and gavaged with H. hepaticus or broth at 3 weeks; necropsied at 40 weeks

2008-06-20 | E-GEOD-11382 | biostudies-arrayexpress

Aflatoxin B1 attenuates endocrine function, protein synthesis and energy production of human primary trophoblast

Project description:Aflatoxin B1 (AFB1) is a mycotoxin produced by Aspergillus flavus and A. parasiticus. AFB1 targeted gene expression profiles were determined in human primary trophoblast cells, isolated from full term placentae after delivery, and exposed to 1 µM AFB1 for 72 hours. Gene expression profiling conducted with human HT-12 expression beadchips

2020-12-31 | GSE153590 | GEO

Liver and cecum from mice exposed to aflatoxin B1 (AFB1) and/or Helicobacter hepaticus

2008-05-09 | GSE11382 | GEO

Genome-Scale CRISPR Knockout Screening Identifies BACH1 as a Key Regulator of Aflatoxin B1-Induced Oxidative Damage [CRISPR screening]

Project description:Aflatoxin B1 (AFB1) is amongst the mycotoxins commonly affecting human and animal health, raising global food safety and control concerns. The mechanisms underlying AFB1 toxicity are poorly understood. Moreover, antidotes against AFB1 are lacking. Genome-wide CRISPR/Cas9 knockout screening in porcine kidney cells identified the transcription factor BTB and CNC homolog 1 (BACH1) as a gene required for AFB1 toxicity. The inhibition of BACH1 expression in porcine kidney cells and human hepatoma cells resulted in increased resistance to AFB1. BACH1 depletion attenuates AFB1-induced oxidative damage via the upregulation of antioxidant genes.

2022-03-25 | GSE199384 | GEO

Mutational signatures of aflatoxin

Project description:Aflatoxin B1 (AFB1) is a mutagen and IARC (International Agency for Research on Cancer) Group 1 carcinogen that causes hepatocellular carcinoma (HCC). Here we present the first whole genome data on the mutational signatures of AFB1 exposure from a total of > 40,000 mutations in four experimental systems: two different human cell lines, and in liver tumors in wild-type mice and in mice that carried a hepatitis B surface antigen transgene – this to model the multiplicative effects of aflatoxin exposure and hepatitis B in causing HCC. AFB1 mutational signatures from all four experimental systems were remarkably similar. We integrated the experimental mutational signatures with data from newly-sequenced HCCs from Qidong County, China, a region of well-studied aflatoxin exposure. This indicated that COSMIC mutational signature 24, previously hypothesized to stem from aflatoxin exposure, indeed likely represents AFB1 exposure, possibly combined with other exposures. Among published somatic mutation data, we found evidence of AFB1 exposure in 0.7% of HCCs treated in North America, 1% of HCCs from Japan, but 16% of HCCs from Hong Kong. Thus, aflatoxin exposure apparently remains a substantial public health issue in some areas. This aspect of our study exemplifies the promise of future widespread resequencing of tumor genomes in providing new insights into the contribution of mutagenic exposures to cancer incidence.

| EGAS00001002490 | EGA

Comparative toxicity of Aflatoxin B1, Patulin and their biosynthetic precursors: A human intestinal microarray analysis

Project description:Patulin (PAT) and Aflatoxin B1 (AFB1) are frequent mycotoxins contaminating food and feed which demonstrate multiple toxic effects. These mycotoxins represent final product in cascades of enzymatic reactions. In order to limit the risk generated by food contamination, approaches aiming to block the biosynthesis pathway of these mycotoxins can be considered, provided that their precursors are devoid of toxicity. The aim of this study was to compare the toxicity of two precursor compounds (Versicolorin A (VERA), sterigmatocystin (STG)) to AFB1 and the precursor compound (ascladiol) to PAT. Human intestinal Caco-2 cells were exposed to 1 µM AFB1, VERA, STG or 3 µM PAT or ascladiol for 24 hours and transcription analysis was performed using an “Agilent Sureprint 63 Human GE 8x60k microarray.

2018-12-31 | GSE75934 | GEO

Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma [mRNA]

Project description:Chronic exposure to aflatoxin B1 (AFB1) has, in certain regions in the world, been strongly associated with the development of hepatocellular carcinoma (HCC). AFB1 is a very potent hepatotoxic and carcinogenic mycotoxin which is frequently reported as a food contaminant. Epigenetic modifications provoked by environmental exposures, such as AFB1, may create a so called persistent "epigenetic memory" or "footprint". Deregulation of epigenetic mechanisms has actually been reported in HCC patients following AFB1 exposure; however no attempts have yet been made to investigate early effects on the epigenome level which may be persistent on longer term thereby possibly initiating carcinogenic events. In this study, we aim to identify methyl DNA-mRNA-interactions representative for a persistent epigenetic "footprint" associated with the early onset of AFB1-induced HCC. For this, primary human hepatocytes were exposed to 0.3 µM of AFB1 for 5 days. Persistent epigenetic effects were m easured 3 days after terminating the carcinogenic treatment. Whole genome DNA methylation changes and whole genome transcriptomic analysis were analyzed applying microarray technologies, and cross-omics interactions were evaluated. Upon combining transcriptomics data with results on DNA methylation, a range of persistent hyper- and hypomethylated genes was identified which appeared also affected on the transcriptome level. For six of the hypomethylated and upregulated genes, namely TXNRD1, PCNA, CCNK, DIAPH3, RAB27A and HIST1H2BF, a clear role in carcinogenic events could be identified. This study is the first to report on a carcinogen-induced persistent impact on the "epigenetic footprint" in relation with the transcriptome which could be indicative for the early onset of AFB1-related development of HCC.

2016-05-10 | GSE71547 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data